Ray Therapeutics' $8M CIRM Grant Funds RTx-015 Trial

Ray Therapeutics received a $7,975,224 grant from the California Institute for Regenerative Medicine to support clinical development of RTx-015, its optogenetic gene therapy for retinitis pigmentosa. CIRM approved the award, numbered CLIN2-17086, on April 24, 2025, and currently lists it as active.

The Berkeley biotechnology company is testing RTx-015 in ENVISION, a Phase 1 study for people with retinitis pigmentosa or choroideremia. The therapy is designed to make surviving retinal cells responsive to light after the photoreceptors that normally perform that job have degenerated.

The award matters because it finances the point where an elegant biological idea has to become interpretable human evidence. Light sensitivity, safety, dose, durability, functional vision and the brain's ability to use a new retinal signal all have to survive clinical measurement.

What CIRM Funded

CIRM awarded nearly $8M to the Phase 1 clinical program, with Ray co-founder and CEO Paul Bresge named as principal investigator. The grant is non-dilutive public funding, not an equity financing round, and its exact value is $7,975,224.

The award followed two earlier CIRM translational grants to Ray. One supported an optogenetic therapy for retinitis pigmentosa and other inherited retinal diseases; the other supported work in geographic atrophy. CIRM's institution record now lists three Ray Therapeutics awards totaling $15,973,707.

That sequence is the more useful part of the capital story. The earlier awards helped advance preclinical and translational work. The clinical-stage award supports the slower job of observing what happens in people, with a protocol, defined doses, safety monitoring and years of follow-up.

Ray announced the grant while ENVISION was already under way. ClinicalTrials.gov lists an actual study start date of August 27, 2024. The current record, last updated in February 2026, describes the trial as active but not recruiting with 10 participants enrolled.

How RTx-015 Is Designed to Restore a Light Signal

Retinitis pigmentosa is a group of inherited retinal diseases in which rods and cones progressively stop working and die. Those photoreceptors normally convert light into signals that move through the retina and toward the brain. Once enough of them are lost, replacing one defective gene may no longer address the practical problem in front of the patient.

RTx-015 takes a mutation-independent route. Ray uses gene therapy to deliver a bioengineered light-sensitive protein to retinal ganglion cells, which can remain after photoreceptor loss. The goal is to make those surviving cells respond to light and send a new signal into the existing visual pathway.

ENVISION evaluates a single injection into one eye. The open-label, non-randomized, dose-escalation Phase 1 study is designed to assess safety and preliminary efficacy in adults with retinitis pigmentosa or choroideremia. The current registry says participants will be followed for five years.

The mechanism widens the theoretical patient population because it is not built around one causative mutation. It also creates a demanding proof burden. A cell responding to light is not the same as a person recovering useful vision. The signal has to be strong enough, safe enough and stable enough for the retina and brain to turn it into function.

The Clinical Evidence Boundary

The U.S. Food and Drug Administration's approved Luxturna indication shows both the promise and the limits of inherited-retinal-disease gene therapy. Luxturna treats patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, a narrowly defined genetic population. Ray is pursuing a different idea: restore photosensitivity downstream of the lost photoreceptors without requiring the same mutation-specific match.

A September 2026 review in Gene Therapy described optogenetic vision restoration as a mutation-agnostic strategy with an expanding clinical pipeline. It also identified unresolved translational barriers, including light sensitivity, immune response, cell targeting and the absence of standardized endpoints for people with profound visual impairment.

Those barriers explain why the grant is more than a funding footnote. Early-stage vision-restoration studies have to measure safety while learning which functional tests capture a change that matters outside the clinic. Navigation, object recognition, visual acuity, contrast and light perception do not describe the same kind of improvement.

Ray has not established an approved treatment, durable clinical benefit or commercial timeline for RTx-015. Phase 1 is the beginning of that evidence chain, and the grant funds the work required to keep the questions measurable rather than promotional.

What Changed After the Grant

Ray has added regulatory and financial momentum since the April 2025 award. The company reported FDA Regenerative Medicine Advanced Therapy designation for RTx-015 in April 2026, followed by European Medicines Agency Priority Medicines designation. Later that month, Ray announced a $125M Series B financing to support late-stage development and commercial readiness across RTx-015 and RTx-021.

Those later milestones do not turn the CIRM award into a retroactive success claim. They show how public translational funding, clinical evidence, regulatory engagement and private capital can occupy different parts of the same development path. CIRM pays for defined research and clinical work; regulators evaluate evidence and development plans; investors finance a larger organization around the programs.

The remaining responsibility stays with the trial. Ray now has more capital, a broader leadership team and regulatory designations that can improve agency interaction. None of those replaces the patient-level evidence required to understand what a new retinal signal can safely do.

Why the $8M Grant Matters

Biotechnology often celebrates the capital that arrives fastest and photographs best. This grant is attached to work that moves at the speed of enrollment, dose escalation, follow-up and careful interpretation. That is exactly where vision restoration becomes less cinematic and more useful.

For Ray, the clinical task is to learn whether one injection can help surviving retinal cells carry a job they were not originally built to perform. For CIRM, the award extends a public funding relationship from translational research into human testing. For patients, every useful result has to travel from a new light-sensitive protein through the retina, into the brain and back out into a life where seeing something must mean being able to use it.